Medtronic (NYSE:MDT) has faced several challenges in the past decade. Some were probably because of poor focus and lack of innovation, while others, like COVID-19, were out of their control.

A series of case reports to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept), describe how a technology giving insulin doses ...

The Medtronic MiniMed pump will serve as one of Tidepool Loop’s accessories ... Tandem’s ground-breaking insulin delivery ...

Last month, the US Food and Drug Administration (FDA) issued a Class I recall for Medtronic’s NIM Vital ... drain and shutdowns of their insulin pumps. "The complexity of medical devices and ...

The study found that patients showed glycaemic improvements with the use of Omnipod 5 compared with traditional methods of insulin injections or pump therapy ... for Disease Control (CDC) found ...

Procyriontm, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the appointment of Lucas Buchanan to the company's ...

Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's ...

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run ...

Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.

Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...